Drugs like Ozempic and Wegovy are linked to a lower risk of Alzheimer’s disease, new study says
A new study reveals that the active ingredient in drugs like Ozempic and Wegovy could lower the risk of developing Alzheimer’s disease.
Read Full Article on FortuneAI SUMMARY
# Investing Summary A new study indicates that GLP-1 receptor agonists—the active ingredient in Novo Nordisk's Ozempic and Wegovy—may reduce Alzheimer's disease risk, potentially expanding the addressable market for these already blockbuster drugs beyond diabetes and weight loss management. This finding could significantly boost valuations for GLP-1 manufacturers like Novo Nordisk, Eli Lilly, and Viking Therapeutics, as neurodegenerative disease prevention represents a massive market opportunity if the results are validated in
MENTIONED STOCKS
More Finance News
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
FBI thwarts ‘radicalized young man’ after undercover sting operation where he bought an assault rifle to attack the Mall of America
Trump’s $2 billion midterms health-care bribe will go to just 20.8 million Americans, less than one-third of Medicare recipients
Trump administration wants schools to pay $70,000 fee for each international student in the OPT work program, as new foreign enrollment falls 17%
Four tribes partner with Kalshi to launch prediction apps–a move that undercuts Native American opposition to the industry
Content sourced from Fortune. Not financial advice.